- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05701189
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
Phase 2, Randomized, Patient- and Rater-blinded Single-site Trial Evaluating Safety and Efficacy of Efgartigimod in Patients With Guillain-Barré Syndrome.
The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are:
- Is Efgartigimod a safe treatment option for GBS patients?
- Does treatment with Efgartigimod improve patient outcomes?
In addition to standard-of-care procedures and assessments, participants will:
- Undergo seven blood draws during hospitalization and in four follow-up study visits to evaluate the concentration of neurofilament light chain, a protein that is elevated in patients with Guillain-Barré syndrome. The presence of neurofilament light chain is believed to be indicative of damage to the nervous system, with higher levels resulting from greater damage.
- Complete the Columbia Suicide Severity Rating Scale (C-SSRS) to monitor any suicidal ideation or behaviors during the course of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The following procedures/assessments are standard-of-care for Guillain-Barré syndrome. They will not be performed solely for research purposes in this study, but the study team will use select results from them to draw conclusions related to this research:
- The study doctor or study staff will ask you about your medical history and any changes to your medications
- You will have a physical examination
- Your vital signs, including blood pressure, pulse rate, breathing rate, body temperature, and weight will be measured
- You will have an electrocardiogram (ECG)
- Pulmonary function testing, including forced vital capacity (FVC), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) will be performed
- Blood samples will be drawn to evaluate disease progression and safety/efficacy of treatment
- You will undergo a lumbar puncture, commonly referred to as a spinal tap, to collect cerebrospinal fluid (CSF) for analysis
- Nerve conduction studies (NCS) will be performed
- Outcome assessments including the GBS Disability Scale (GBS-DS), Neuropsychological Impairment Scale (NIS), and Inflammatory Rasch-built Overall Disability Scale (I-RODS) will be performed
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kelsey Moulton
- Phone Number: 267-593-9459
- Email: kelsey.moulton@pennmedicine.upenn.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18 years or older
- Have a diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for Guillain-Barré Syndrome
- Onset of GBS-related weakness ≤14 days prior to infusion
- GBS-DS score of 3, 4, or 5
Exclusion Criteria:
- Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing. Women of childbearing potential should have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline prior to administration of IMP. Note: Women of childbearing potential should use a highly effective method of contraception (i.e., pregnancy rate of less than 1% per year) during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month, of combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or agree upon continuous abstinence from heterosexual sexual contact.
- Male patients who are sexually active and do not intend to use effective methods of contraception (as mentioned above) during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing. Note: Sterilized male patients who have had vasectomy with documented aspermia post-procedure, or male patients who have a partner of non-childbearing potential, can be included.
- GBS DS of 2 or less.
- Patients with any known severe bacterial, viral or fungal infection or any major episode of infection that required hospitalization or injectable antimicrobial therapy in the last 8 weeks prior to Screening.
- Patients with more than 14 days after onset of symptoms.
- Patients with known IgG deficiency.
- Patients with recurrent GBS.
- Use of investigational drug within 3 months or 5 half-lives of the drug (whichever is longer) prior to Screening.
- Patients who have a history of malignancy, including malignant thymoma, or myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 3 years before Screening. Patients with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.
- Patients with clinical evidence of other significant serious disease or patients who underwent a recent major surgery, which could confound the results of the trial or put the patient at undue risk. Patients with renal/hepatic function impairment can be included.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Efgartigimod Alfa-Fcab
20mg/kg of Intravenous efgartigimod on days 1 and 5, with normal saline administered as placebo on days 2-4
|
Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment.
The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation.
Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged.
This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
Other Names:
|
Active Comparator: Intravenous Immunoglobulin (IVIg)
0.4g/kg of IVIg daily for 5 days
|
IVIg is the standard-of-care treatment for GBS.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Guillain-Barre Syndrome Disability Scale (GBS-DS)
Time Frame: 12 weeks
|
Scoring system that assesses the functional status of GBS subjects.
Scores range from 0 to 6, with higher scores indicating a worse outcome.
|
12 weeks
|
Number and seriousness of adverse events
Time Frame: Through study completion, an average of 3 years
|
Safety monitoring
|
Through study completion, an average of 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Guillain-Barre Syndrome Disability Scale (GBS-DS)
Time Frame: 4, 24, and 48-weeks
|
Scoring system that assesses the functional status of GBS subjects.
Scores range from 0 to 6, with higher scores indicating a worse outcome.
|
4, 24, and 48-weeks
|
Neuropathy Impairment Scale (NIS)
Time Frame: 4, 24, and 48-weeks
|
Peripheral neuropathy assessment.
Scores range from 0 to 244, with higher scores indicating a worse outcome.
|
4, 24, and 48-weeks
|
Inflammatory Rasch-Built Overall Disability Scale (I-RODS)
Time Frame: 4, 24, and 48-weeks
|
Functional outcome assessment.
Scores range from 0 to 48, with higher scores indicating a better outcome.
|
4, 24, and 48-weeks
|
Forced Vital Capacity (FVC)
Time Frame: 4, 24, and 48-weeks
|
Pulmonary function test that measures the maximum amount of air you can forcibly exhale from your lungs after fully inhaling.
Units are Liters and percentages, when comparing to a predicted value.
|
4, 24, and 48-weeks
|
Maximal Inspiratory Pressure (MIP)
Time Frame: 4, 24, and 48-weeks
|
Pulmonary function test that evaluates the strength of inspiratory muscles, primarily the diaphragm.
Units are cm H2O (centimeters of water).
|
4, 24, and 48-weeks
|
Maximal Expiratory Pressure (MEP)
Time Frame: 4, 24, and 48-weeks
|
Pulmonary function test that evaluates the strength of expiratory muscles.
Units are cm H2O (centimeters of water).
|
4, 24, and 48-weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarker levels: Neurofilament Light (Nf-L) Chain
Time Frame: Baseline and weeks 1, 4, 12, 24, and 48.
|
Exploratory assessment requiring blood collection
|
Baseline and weeks 1, 4, 12, 24, and 48.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Madeline Singer, MD, Staff Physician and Neuromuscular Research Fellow
- Principal Investigator: Chafic Karam, MD, Staff Physician and Associate Professor of Clinical Neurology
- Study Director: Colin Quinn, MD, Staff Physician and Associate Professor of Clinical Neurology
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Disease Attributes
- Disease
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Polyradiculoneuropathy
- Polyneuropathies
- Chronic Disease
- Post-Infectious Disorders
- Syndrome
- Guillain-Barre Syndrome
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
Other Study ID Numbers
- 852292
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Guillain-Barre Syndrome
-
Mansoura University HospitalUnknownGuillain Barre SyndromeEgypt
-
University Hospital, Basel, SwitzerlandRecruitingGuillain-Barre Syndrome (GBS)Switzerland
-
Ning Wang, MD., PhD.Recruiting
-
Mansoura University Children HospitalCompletedGuillain Barre SyndromeEgypt
-
Hoffmann-La RocheChugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)Withdrawn
-
Annexon, Inc.International Centre for Diarrhoeal Disease Research, Bangladesh; ResearchPoint...CompletedGuillain-Barré SyndromeDenmark, Bangladesh
-
International Centre for Diarrhoeal Disease Research...Erasmus Medical Center; GBS-CIDP Foundation International; National Institute...CompletedGuillain-Barré SyndromeBangladesh
-
Nihon Pharmaceutical Co., LtdCompletedGuillain-Barré SyndromeJapan
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownGullian Barre SyndromeUnited Kingdom
-
Cellenkos, Inc.Withdrawn
Clinical Trials on Efgartigimod Alfa-Fcab
-
Shanghai Zhongshan HospitalNot yet recruitingMyasthenia Gravis
-
argenxCompleted
-
argenxRecruitingGeneralized Myasthenia GravisUnited States, Netherlands, Belgium, Poland, United Kingdom
-
argenxCompletedGeneralized Myasthenia GravisSpain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
-
argenxNot yet recruiting
-
argenxIqvia Pty LtdRecruitingPrimary Sjögren's SyndromeBelgium, Hungary, Poland
-
argenxIqvia Pty LtdRecruitingPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia SyndromeUnited States
-
argenxNot yet recruiting
-
argenxRecruitingGeneralized Myasthenia GravisUnited Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
-
argenxIqvia Pty LtdActive, not recruitingPostural Orthostatic Tachycardia SyndromeUnited States